Hepatosplenic T-cell lymphomas and therapy with TNF-α-blocking biologics: A risk for psoriasis patients?;Hepatosplenisches T-Zell-Lymphom unter Therapie mit TNF-α- inhibierenden Biologics: (k)ein Risiko für Patienten mit Psoriasis?

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 3, 2009, Pages 191-195

  Beyer, Marc ^a   Steinhoff, Matthias ^a   Anagnostopoulos, Ioannis ^a   Assaf, Chalid ^a   Sterry, Wolfram ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biologics; Hepatosplenic T cell lymphoma; Inflammatory bowel disease; Psoriasis vulgaris; TNF antagonists

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; GRANULOMATOUS INFLAMMATION; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; PSORIASIS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; T CELL LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; TISSUE SPECIFICITY; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; HUMANS; LYMPHOMA, T-CELL; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61449113926     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06961.x     Document Type: Article

References (20)

1. Belhadj K, Reyes F, Farcet JP, Tilly H, Bastard C, Angonin R, Deconinck E, Charlotte F, Leblond V, Labouyrie E, Lederlin P, Emile JF, Delmas-Marsalet B, Arnulf B, Zafrani ES, Gaulard P. Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003 102 : 4261 4269.
2. Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leuk Lymphoma 2007 48 : 1410 1413.
3. Mackey AC, Green L, Liang L, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007 44 : 265 267.
4. Thayu M, Markowitz JE, Mamula P, Russo PA, Muinos WI, Baldassano RN. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodu-lator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005 40 : 220 222.
5. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007 13 : 1024 1030.
6. Rote-Hand-Brief, Abbott GmbH & Co. KG, 07/2008.
7. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002 46 : 3151 3158.
8. Khan WA, Yu L, Eisenbrey AB, Crisan D, Al Saadi A, Davis BH, Hankin RC, Mattson JC. Hepatosplenic gamma/delta T-Cell Lymphoma in Immunocompro-mised Patients. Report of Two Cases and Review of Literature. Am J Clin Pathol 2001 116 : 41 50.
9. Steurer M, Stauder R, Grunewald K, Gunsilius E, Duba H-C, Gastl G, Dirnhofer S. Hepatosplenic γδ T-cell lymphoma with leukemic course after renal transplantation. Hum Pathol 2002 33 : 253 258.
10. Navarro JT, Ribera JM, Mate JL, Granada I, Juncà J, Batlle M, Millá F, Feliu E. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003 44 : 531 533.
11. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized double-blind, placebo-controlled trial. Gastroenterol 2001 121 : 1088 1094.
12. Wallis RS, Ehlers S. Tumor Necrosis Factor and Granuloma Biology: Explaining the Differential Infection Risk of Etanercept and Infliximab. Semin Arthritis Rheum 2005 34 (Suppl 1 34 38.
13. Przybylski GK, Wu H, Macon WR, Finan J, Leonard DGB, Felgar RE, DiGiuseppe JA, Nowell PC, Swerdlow SH, Kadin ME, Wasik MA, Salhany KE. Hepatosplenic and subcutaneous panniculitis-like γδ T cell lymphomas are derived from different Vδ subsets of γδ T lymphocytes. J Mol Diag 2000 2 : 11 19.
14. McVay LD, Li B, Biancaniello R, Creighton MA, Bachwich D, Lichtenstein G, Rombeau JL, Carding SR. Changes in human mucosal γδ T cell repertoire and function associated with the disease process in inflammatory bowel disease. Mol Med 1997 3 : 183 203.
15. Seung NR, Park EJ, Kim CW, Kim KH, Kim KJ, Cho HJ, Park HR. Comparison of expression of heat-shock protein 60, toll-like receptors 2 and 4, and T-cell receptor gammadelta in plaque and guttate psoriasis. J Cutan Pathol 2007 34 : 903 911.
16. Giacomelli R, Parzanese I, Fieri G, Passacantando A, Pizzuto F, Pimpo T. Increase of Cipriani P, Viscido A, Caprilli R, Tonietti G. Circulating γ/δ T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease. Clin Exp Immunol 1994 98 : 83 88.
17. Spadaro A, Scrivo R, Moretti T, Bernardini G, Riccieri V, Taccari E, Strom R, Valesini G. Natural killer cells and gamma/delta T cells in synovial fluid and in peripheral blood of patients with psoriatic arthritis. Clin Exp Rheumatol 2004 22 : 389 394.
18. Söderström K, Bucht A, Halapi E, Grönberg A, Magnusson I, Kiessling R. Increased frequency of abnormal γδ T cells in blood of patients with inflammatory bowel diseases. J Immunol 1996 156 : 2331 2339.
19. Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS. Aggressive cutaneous T-cell lymphomas after TNFα blockade. J Am Acad Dermatol 2004 51 : 660 662.
20. Michaëlsson G, Kraaz W, Gerdén B, Hagforsen E, Hjelmqvist G, Lööf L, Sjöberg O, Scheynius A. Increased lymphocyte infiltration in duodenal mucosa from patients with psoriasis and serum IgA antibodies to gliadin. Br J Dermatol. 1995 133 : 896 904.